LYNPARZA is approved as a first-line maintenance therapy for certain patients with advanced ovarian cancer after the cancer has responded to platinum-based chemotherapy. It can be taken alone or in combination with the medicine bevacizumab. Talk to your doctor about getting tested to see if LYNPARZA is right for you.

LYNPARZA is used as a maintenance therapy and can be taken alone or in combination with the medicine bevacizumab.

LYNPARZA in combination

LYNPARZA + bevacizumab may give adults more time without their HRD-positive advanced ovarian cancer growing or returning compared to bevacizumab.*

*LYNPARZA + bevacizumab was studied against bevacizumab + placebo.

A clinical study evaluated patients with advanced ovarian cancer who received LYNPARZA + bevacizumab after responding to first-line platinum-based chemotherapy and bevacizumab. The results below are from a subset of a study and should be discussed with your doctor. In the subset of 387 patients with HRD-positive advanced ovarian cancer, 255 patients received LYNPARZA + bevacizumab and 132 patients received bevacizumab + placebo.

LYNPARZA + bevacizumab lowered the risk of disease progression or death by 67% compared to bevacizumab + placebo.

168 out of 255 patients on LYNPARZA + bevacizumab did not see their cancer grow or return compared with 40 out of 132 patients on bevacizumab + placebo.

67%

Lower risk of disease progression or death

LYNPARZA + BEVACIZUMAB

37.2 Months 37.2 Months

37.2 months

BEVACIZUMAB + PLACEBO

17.7 Months 17.7 Months

17.7 months

Adults receiving LYNPARZA + bevacizumab were alive and did not see their HRD-positive advanced ovarian cancer grow or return for a median of over 3 years (37.2 months) compared with over 1 year (17.7 months) for adults on bevacizumab + placebo.

Based on the design of this study, the statistical meaning of these results may be limited. Talk to your doctor to see if LYNPARZA + bevacizumab is right for you.

LYNPARZA alone

LYNPARZA could give adults with BRCA-mutated advanced ovarian cancer more time progression free after responding to first-line platinum-based chemotherapy

A clinical study included 391 patients with a BRCA mutation and advanced ovarian cancer after they responded to first-line platinum-based chemotherapy. 260 patients took LYNPARZA and 131 took placebo.

70%

Lower risk of disease progression or death

At a median follow-up of 3.4 years (41 months), LYNPARZA lowered the risk of disease progression or death by 70% compared with placebo.

61% of patients (158 out of 260) taking LYNPARZA were alive and did not see their cancer grow or return at a median follow-up of 3.4 years (41 months) compared with 27% of patients (35 out of 131) on placebo.

LYNPARZA

 
 
61%

158 OUT OF 260 PATIENTS

vs

PLACEBO

 
 
27%

35 OUT OF 131 PATIENTS

Talk to your doctor about getting tested to see if LYNPARZA is right for you.